×
Grace Therapeutics EBITDA 2014-2024 | GRCE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Grace Therapeutics ebitda from 2014 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Grace Therapeutics EBITDA 2014-2024 | GRCE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Grace Therapeutics ebitda from 2014 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$160.6B
Vertex Pharmaceuticals (VRTX)
$126.2B
Bristol Myers Squibb (BMY)
$119.7B
Gilead Sciences (GILD)
$117.5B
Regeneron Pharmaceuticals (REGN)
$90.2B
CSL (CSLLY)
$90B
GSK (GSK)
$73.6B
Argenex SE (ARGX)
$35.5B
Alnylam Pharmaceuticals (ALNY)
$34.7B
BioNTech SE (BNTX)
$25.5B
Biogen (BIIB)
$24.5B
Illumina (ILMN)
$23.4B
BeiGene (BGNE)
$18.9B
Moderna (MRNA)
$16.7B
Incyte (INCY)
$15.5B
Genmab (GMAB)
$14.9B
BioMarin Pharmaceutical (BMRN)
$12.6B
Insmed (INSM)
$12.5B
Vaxcyte (PCVX)
$12.4B
Bio-Techne Corp (TECH)
$11.8B
Sarepta Therapeutics (SRPT)
$10.9B
Exelixis (EXEL)
$10.2B
Revolution Medicines (RVMD)
$10B
QIAGEN (QGEN)
$9.9B
Intra-Cellular Therapies (ITCI)
$9.4B
Bio-Rad Laboratories (BIO.B)
$9.4B
Exact Sciences (EXAS)
$9.3B
Roivant Sciences (ROIV)
$8.6B
Repligen (RGEN)
$8.3B
Ascendis Pharma (ASND)
$7.7B